Introduction: The canonical isocitrate dehydrogenase 1 R132 mutation (IDH1 R132) is the most frequent mutation among IDH-mutated gliomas. Non-canonical IDH1 mutations or IDH2 mutations are unusual and their clinical and biological role is still unclear. Methods: We performed a systematic review and meta-analysis to assess the clinical role of IDH non-canonical mutations. Results: Overall, we selected 13 of 3513 studies reporting data of 4007 patients with a diagnosis of grade 2 and grade 3 glioma including 3091 patients with a molecularly proven IDH1 or IDH2 mutation. Patients with non-canonical IDH1 mutations were younger and presented a higher DNA methylation level as compared to those with canonical IDH1 R132H alteration. The overall incidence of non-canonical IDH1 mutations was 7.9% (95% CI 5.4-10.7%) in patients with IDH-mutated gliomas. There was no statistical difference in terms of incidence between patients with grade 2 or grade 3 glioma. Patients with non-canonical IDH mutations had a lower rate of 1p19q codeletion (risk difference 31%, 95% CI 23-38%) and presented a significantly prolonged survival (pooled HR 0.47, 95% CI 0.28-0.81) as compared to those with IDH1 R132H mutation. Conclusion: Non-canonical IDH1 mutations occur in 7.9% of IDH-mutated gliomas and identify a specific subgroup of patients with an improved survival despite a lower rate of 1p19q codeletion. Data about the type of IDH mutation should be collected in clinical practice and within interventional trials as this could be a critical variable for improved stratification and selection of patients.

Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis / Vincenzo Di Nunno , Enrico Franceschi , Alicia Tosoni , Lidia Gatto , Ilaria Maggio , Raffaele Lodi , Daniele Angelini , Stefania Bartolini , Alba Ariela Brandes. - In: ADVANCES IN THERAPY. - ISSN 1865-8652. - ELETTRONICO. - 39:1(2022), pp. 165-177. [10.1007/s12325-021-01977-3]

Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.

Vincenzo Di Nunno;Enrico Franceschi;Lidia Gatto;Ilaria Maggio;Raffaele Lodi;
2022

Abstract

Introduction: The canonical isocitrate dehydrogenase 1 R132 mutation (IDH1 R132) is the most frequent mutation among IDH-mutated gliomas. Non-canonical IDH1 mutations or IDH2 mutations are unusual and their clinical and biological role is still unclear. Methods: We performed a systematic review and meta-analysis to assess the clinical role of IDH non-canonical mutations. Results: Overall, we selected 13 of 3513 studies reporting data of 4007 patients with a diagnosis of grade 2 and grade 3 glioma including 3091 patients with a molecularly proven IDH1 or IDH2 mutation. Patients with non-canonical IDH1 mutations were younger and presented a higher DNA methylation level as compared to those with canonical IDH1 R132H alteration. The overall incidence of non-canonical IDH1 mutations was 7.9% (95% CI 5.4-10.7%) in patients with IDH-mutated gliomas. There was no statistical difference in terms of incidence between patients with grade 2 or grade 3 glioma. Patients with non-canonical IDH mutations had a lower rate of 1p19q codeletion (risk difference 31%, 95% CI 23-38%) and presented a significantly prolonged survival (pooled HR 0.47, 95% CI 0.28-0.81) as compared to those with IDH1 R132H mutation. Conclusion: Non-canonical IDH1 mutations occur in 7.9% of IDH-mutated gliomas and identify a specific subgroup of patients with an improved survival despite a lower rate of 1p19q codeletion. Data about the type of IDH mutation should be collected in clinical practice and within interventional trials as this could be a critical variable for improved stratification and selection of patients.
2022
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis / Vincenzo Di Nunno , Enrico Franceschi , Alicia Tosoni , Lidia Gatto , Ilaria Maggio , Raffaele Lodi , Daniele Angelini , Stefania Bartolini , Alba Ariela Brandes. - In: ADVANCES IN THERAPY. - ISSN 1865-8652. - ELETTRONICO. - 39:1(2022), pp. 165-177. [10.1007/s12325-021-01977-3]
Vincenzo Di Nunno , Enrico Franceschi , Alicia Tosoni , Lidia Gatto , Ilaria Maggio , Raffaele Lodi , Daniele Angelini , Stefania Bartolini , Alba Ariela Brandes
File in questo prodotto:
File Dimensione Formato  
DiNunno2022_Article_ClinicalAndMolecularFeaturesOf.pdf

accesso riservato

Descrizione: Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis
Tipo: Versione (PDF) editoriale
Licenza: Licenza per accesso riservato
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Contatta l'autore
f4c18143-8fc2-469f-8d89-b9caf1c3bbbf.pdf

accesso aperto

Tipo: Preprint
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/864782
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact